Source: Canada.com
Date: April 10, 2007
Summary:
Stem Cell Therapeutics Corp. (TSXV:SSS) reported it received "positive" interim results from a Phase 2a safety trial study for an acute stroke treatment. The Calgary-based drug developer said the trial of the combined treatments labelled NTx-265 could be safely administered to a population of patients with acute stroke.
